成都看小腿血管炎好的医院(成都静脉扩张的治疗费用) (今日更新中)

BERLIN, June 10 (Xinhua) -- The German state of North Rhine-Westphalia said Friday it detected for the first time the deadly E.coli strain o104 on bean sprouts, after they were named the source of the outbreak by Germany's national disease control centre. "According to our knowledge, the bean sprouts are coming from the recent suspicious farm in Bienenbuettel in the state of Lower Saxony," said Johannes Remmel, consumer protection minister.The sprouts were found in an opened package which had been left in a dustbin of a family, living near the city of Bonn. Two of the family members had eaten the sprouts and contracted the E. coli infection in mid-May, he said.A notice warning consumers not to eat raw bean sprouts is seen at a market in Berlin, capital of Germany, June 10, 2011. The German authority said on Friday bean sprouts were probably the source of the E. coli outbreak, which has killed 30 people and infected about 3,000 around the world. Reinhard Burger, president of the Robert Koch Institute (RKI), Germany's national disease control center said the Robert Koch Institute was lifting its warning against eating cucumbers, tomatoes and lettuce but keeping the warning in place for the sprouts."The discovery confirms our current warning against the consumption of bean sprouts. It is therefore becoming increasingly more likely that bean sprouts are the source of the E.coli infections," Remmel said.The news came after Reinhard Burger, President of the Robert Koch Institute (RKI), said in the morning bean sprouts were the source for the outbreak based on a epidemiological investigation."People who ate (bean) sprouts were found nine times more likely to have bloody diarrhoea or other signs of E. coli infection than those who did not," he saidHowever, no sample tests had found the o104 strain on bean sprouts when he announced that conclusion. Laboratory tests have shown Germany made mistakes in identifying the outbreak source on two previous occasions.At the same time, RKI lifted the warning against cucumbers, tomatoes and lettuce."Enjoy lettuce, cucumbers and tomatoes. They are healthy for you," said Andreas Hensel, president of the German Federal Risk Assessment Institute (BFR), which is a co-leader in the action against E. coli.In the city of Hamburg, an epicentre for the disease, farmers protested in the city centre by offering tons of lettuce and cucumbers for free to anyone who wanted them when the news was announced. Suddenly, pedestrians turned from reluctant to eager takers, reported local news agency DPA.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BRUSSELS, May 31 (Xinhua) -- Baby bottles containing the substance Bisphenol A (BPA) would have to be pulled from the shelves across the European Union (EU) starting from Wednesday, in a "milestone" move to better protect the health of EU citizens, an official said Tuesday."Due to the fact that there are uncertainties concerning the effect of the exposure of infants to Bisphenol A, the commission deemed it both necessary and appropriate to take action," said John Dalli, EU Health and Consumer Policy Commissioner."The aim is to further reduce the exposure of the most vulnerable part of our population, i.e. infants," he said.The ban, adopted in an EU directive in late January, would prohibit baby bottles containing BPA from placing on the EU market and import into the 27-member EU from June 1.Previously, the bloc had already banned the manufacture of the controversial baby bottles on March 1, and the industry has been withdrawing such products voluntarily.BPA is an organic molecule that is used in the manufacture of polycarbonate plastics, which are used to manufacture plastic materials, such as baby bottles.Traces of BPA can be released from plastic containers into the food they carry if these containers are heated at high temperatures. They may lead to early sexual development of children and could cause cancer, according to health officials.China would also prohibit the manufacture of feeding bottles containing BPA from June 1, while imports and sales of bottles containing BPA would be banned starting from Sept. 1.

BEIJING, June 28 (Xinhuanet) -- The figure of adults with diabetes has risen to 347 million worldwide, which is more than doubled in the past three decades, according to a study published in the British journal Lancet.The study, which analyzed data compiled from 2.7 million participants aged 25 and over from across the world, shows approximately 138 million in China have diabetes, and 36 million in the United States.Among high-income countries, diabetes rates were the highest in the U.S., Greenland, Malta, New Zealand, and Spain. The Netherlands, Austria, and France boasted the lowest rates, suggested the study published online by The Lancet journal on June 25.Majid Ezzati, a lead author of the study, said on Reuters: “Diabetes is becoming more common almost everywhere in the world.”Danaei added: “Unless we develop better programs for detecting people with elevated blood sugar and helping them to improve their diet and physical activity and control their weight, diabetes will inevitably continue to impose a major burden on health systems around the world.”

SAN FRANCISCO, July 19 (Xinhua) -- Apple Inc. on Tuesday reported strong third fiscal quarter results that top analysts' expectations, citing strong iPhone and iPad sales.For its fiscal 2011 third quarter ended on June 25, Apple reported net income of 7.31 billion U.S. dollars or 7.79 dollars per share, compared with 3.25 billion dollars, or 3.51 dollars per share a year ago.Its revenue reached 28.57 billion dollars, compared with 15.7 billion dollars in the same period a year earlier. International sales accounted for 62 percent of the quarter's revenue.The average estimate is a profit of 5.84 dollars a share on revenue of 24.9 billion dollars.The Cupertino, Califronia-based company sold 20.34 million iPhones in the quarter, representing 142 percent unit growth over the year-ago quarter. It sold 9.25 million iPads in the third quarter, a 183 percent unit increase on a year-over-year basis.The only drawback is the sales of iPods, which had a 20 percent unit decline to 7.54 million from the year-ago quarter."We're thrilled to deliver our best quarter ever, with revenue up 82 percent and profits up 125 percent," Steve Jobs, Apple's chief executive officer, said in a statement."Right now, we're very focused and excited about bringing iOS 5 and iCloud to our users this Fall," added Job.It is the first time since 2008 that Apple's third-quarter earnings does not include the release of a new iPhone, which, slated for launch in September, is reportedly to be thinner and lighter with a faster chip and 8-megapixel camera.Apple has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. It had previously beaten the average earning projection for at least 29 straight quarters, according to data compiled by Bloomberg.For the fourth fiscal quarter of 2011, Apple's chief financial officer Peter Oppenheimer said the company expects revenue of 25 billion dollars and earnings per share of about 5.5 dollars. Apple has been known for its conservative projections of earnings.Apple has been operating without the daily attention of Jobs since the CEO took a medical leave this January. The Wall Street Journal reported Tuesday that some members of Apple's board have discussed CEO succession with executive recruiters and at least one head of a high-profile technology company.But the people familiar with the matter told the newspaper that it was more of an informal exploration of the company's options and don't appear to have been acting on behalf of the full board.Meanwhile, Apple has recently been busy with a number of legal battles over patent rights with HTC, Eastman Kodak and Samsung.Last week, the U.S. International Trade Commission made an initial ruling that HTC infringed two of Apple's phone patents in its smartphones powered by Google's Android operating system.If upheld, the ruling could let Apple force other Android phone makers to pay significant patent fees.On Tuesday, Google's executive chairman Eric Schmidt said at a conference in Tokyo that Apple's smartphone lawsuits are inspired by jealousy and a lack of innovation in iPhone, noting Google would support HTC's fight against Apple and was confident of a win.

来源：资阳报